Form 4: Director Zeiher Acquires Entrada Therapeutics Stock

Director Bernhardt G. Zeiher acquired 5,000 shares of common stock in Entrada Therapeutics, Inc. for approximately $5.86 per share.

Summary

• Bernhardt G. Zeiher, a Director at Entrada Therapeutics, Inc., purchased 5,000 shares of common stock on May 20, 2026.
• The transaction was executed at a weighted average price of $5.86 per share, with individual purchase prices ranging from $5.86 to $6.00.
• Following this transaction, Zeiher beneficially owns 5,000 shares, held indirectly through the Bernhardt G. Zeiher and Paula B. Zeiher Revocable Living Trust Agreement.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it indicates a director's personal investment, suggesting confidence, but provides no operational or financial performance data.

Positives

• Director's personal investment in the company's stock, indicating confidence in the company's future prospects.
• Acquisition of shares at a price point that may be considered attractive by some investors.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it solely reports a change in beneficial ownership.

Industry Context

StockSavvy.ai notes that insider purchases, such as this one by Director Zeiher, can sometimes signal management's positive view of the company's valuation and future performance, especially in the biotechnology sector where such investments can be a strong indicator.

Stakeholder Impact

• Shareholders may view this director's purchase as a positive signal of confidence in the company's future.
• The transaction itself does not directly impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

Entrada Therapeutics, TRDA, Form 4, Insider Trading, Stock Acquisition, Director Purchase, Beneficial Ownership